Megan K. Doyle

Megan K. Doyle

Auto-generated profile, based on publicly available information

Megan K. Doyle

Amgen, Thousand Oaks, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
ABAmy Bertha
Amy Bertha
RARinol Alaj
Rinol Alaj
IBImein Bousnina
Imein Bousnina
MDMegan K. Doyle
Megan K. Doyle
DFDanielle Friend
Danielle Friend
SRSven Reimann
Sven Reimann
Digital health technologies (DHTs) enable remote data collection, support a patient-centric approach to drug development, and provide real-time data in real-world settings. With increasing use of DHTs in clinical care and development, we expect a growing body of evidence supporting use of DHTs to capture endpoint data in clinical trials. As the body of evidence grows, it will be critical to ensure that available prior work can be leveraged. We propose a framework to reuse analytical and clinical validation, as well as verification data, generated for existing DHTs. We apply real life case studies to illustrate our proposal aimed at leveraging prior work, while applying the V3 framework (verification, analytical validation, clinical validation) and avoiding duplication. Utilizing our framework will enable stakeholders to share best practices and consistent approaches to employing these tools in clinical studies, build on each other’s work, and ultimately accelerate evidence generation demonstrating the reproducibility and value add of these new tools.

4 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TYTimothy A. Yap
Timothy A. Yap
JBJulie Bullock
Julie Bullock
SCSusan Chong
Susan Chong
MDMegan K. Doyle
Megan K. Doyle
AHAzher Hussain
Azher Hussain
VUVijay V. Upreti
Vijay V. Upreti
The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for single agents, but multiple oncology drugs are being developed for use in combination with other therapies. Dose optimization in the context of combination drug development is complex and requires a case-by-case approach. It necessitates commitment to the totality of available evidence, leveraging all relevant data on mechanism of action, nonclinical and clinical pharmacology, safety, and principles of model-informed drug development. In this article, we outline key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens. We illustrate important strategies for dose optimization in the combination setting using a range of hypothetical case examples that represent typical drug development scenarios. Close discussions and collaboration with regulators regarding the optimal approaches to these scenarios will continue to be critical.